Saturday 17 October 2026 Export FLNA’s income statement to Excel — free account

Cassava Sciences, Inc.

In the quarter to June 2026, EPS grew 80.4% and free cash flow grew 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.71 0.05 −6.58%

Follow FLNA

Alert me

Market cap: $36.8M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	3	—	—	—	—	—	—	—	—	—	2	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 2.87%

Capital & Financial Ratios $m

Market Cap 36.75

Revenue 41.12

Net Income (42.28)

Free Cash Flow (29.36)

Net Debt (82.68)

Current Ratio 2.08

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.54

Past 5Y EPS Growth —

This Y EPS Growth 52.39%

Next Y EPS Growth (32.96%)

Next Y revenue growth —

Next 5Y EPS Growth 14.38%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 0.92%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	121	129	96	83
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	130	137	98	84

	2023	2024	2025	Q'26
Payables	11	8	42	39
ST’ Debt	—	—	—	—
Other	0	0	0	0
	14	12	44	40

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	34.74%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	9.74%	(4.20%)	(31.11%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(4)	—	—	—
’25	(11)	(5)	(6)	(10)	(32)
’24	(19)	(18)	(18)	(61)	(117)
’23	(13)	(20)	(27)	(22)	(82)
’22	(24)	(11)	(22)	(21)	(78)
’21	(2)	(5)	(15)	(8)	(30)
’20	(1)	(1)	(2)	(1)	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(4)	—	—	—
’25	(11)	(5)	(6)	(10)	(33)
’24	(19)	(18)	(18)	(61)	(117)
’23	(14)	(20)	(27)	(22)	(82)
’22	(24)	(13)	(23)	(21)	(80)
’21	(2)	(5)	(37)	(8)	(52)
’20	(1)	(1)	(2)	(1)	(5)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.21)	(0.18)	—	—	—
’25	(0.48)	(0.92)	(0.22)	(0.26)	(1.88)
’24	0.57	0.13	(0.58)	(0.57)	(0.52)
’23	(0.58)	(0.63)	(0.61)	(0.50)	(2.32)
’22	(0.44)	(0.48)	(0.51)	(0.47)	(1.90)
’21	(0.09)	(0.13)	(0.24)	(0.35)	(0.82)
’20	(0.05)	(0.05)	(0.06)	(0.09)	(0.24)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.57	3.10	0.76	0.84	1.63	6.78	13.84	12.32	2.23	1.15	Analyst estimates 2026–2028 Powerpack
	High	21.00	9.31	12.80	7.20	12.68	146.16	62.49	38.53	42.20	4.98
People
People	Employees	9	9	9	9	11	24	26	29	30	17
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(15)	(12)	(7)	(5)	(6)	(32)	(76)	(97)	(24)	(91)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(15)	(12)	(7)	(5)	(6)	(32)	(76)	(97)	(24)	(91)
	Depreciation	0	0	0	0	0	1	1	2	1	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(2.31)	(1.82)	(0.61)	(0.27)	(0.24)	(0.82)	(1.90)	(2.32)	(0.53)	(1.88)
	Cash flow	(1.88)	(1.26)	(0.45)	(0.14)	(0.21)	(0.77)	(1.93)	(1.96)	(2.52)	(0.67)
	Capex	(0.01)	0.00	0.00	0.00	0.01	(0.56)	(0.07)	(0.01)	0.00	(0.01)
	Free cash flow	(1.89)	(1.26)	(0.45)	(0.15)	(0.19)	(1.33)	(2.00)	(1.97)	(2.53)	(0.68)
	Book value	2.86	1.48	1.84	1.27	3.53	6.44	5.66	3.28	3.15	1.54
	Shares, m	7	7	11	17	26	39	40	42	46	48
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(12)	(8)	(5)	(3)	(5)	(30)	(78)	(82)	(117)	(32)
	Capex	0	—	—	0	0	(22)	(3)	0	0	(1)
	Free cash flow	(12)	(8)	(5)	(3)	(5)	(52)	(80)	(82)	(117)	(33)
Balance, $m
Balance, $m	Working capital	18	10	20	22	92	232	204	115	125	54
	Total debt	—	—	—	0	0	0	0	—	—	—
	Net debt	(19)	(10)	(20)	(23)	(94)	(233)	(201)	(121)	(129)	(96)
	Shareholders’ equity	19	10	20	22	92	254	228	137	146	74
Returns, %
Returns, %	ROA	(57.99)	(79.06)	(42.34)	(21.23)	(10.76)	(17.94)	(30.40)	(50.31)	(15.75)	(65.95)
	ROIC	0.00	0.00	0.00	0.00	0.00	(100.31)	(188.56)	(405.48)	(516.08)	0.00
	ROE	(61.87)	(84.07)	(44.72)	(22.20)	(11.08)	(18.71)	(31.67)	(53.27)	(17.19)	(82.66)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2013 · latest quarter Dec 2013

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LBPS 4D pharma PLC Sponsored ADR	$37.2M	— (loss-making)	—	+41.64% (above 0%: growing)	n/m	−16,367.69% (below 0%: shrinking)	0.00%	0.00%	Compare
EXOZ eXoZymes Inc.	$37.1M	— (loss-making)	—	—	n/m	−3.25% (below 0%: shrinking)	—	0.00%	Compare
FLNA Cassava Sciences, Inc.	$36.8M	— (loss-making)	—	+1,328.04% (above 0%: growing)	n/m	+21.65% (above 0%: growing)	0.00%	0.00%
LITS Lite Strategy, Inc.	$36.3M	— (loss-making)	— (loss-making)	+647.96% (above 0%: growing)	n/m	+179.28% (above 0%: growing)	0.00%	0.00%	Compare
EDSA Edesa Biotech, Inc.	$36.1M	— (loss-making)	— (loss-making)	−99.88% (below 0%: shrinking)	n/m	−81.24% (below 0%: shrinking)	0.00%	0.00%	Compare
NNVC NanoViricides, Inc.	$35.0M	— (loss-making)	—	—	n/m	−23.94% (below 0%: shrinking)	0.00%	0.00%	Compare
LIANY LianBio Sponsored ADR	$34.2M	0.0×	—	—	n/m	+1,107.59% (above 0%: growing)	0.00%	0.00%	Compare
CRVO CervoMed Inc.	$34.0M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−6.20% (below 0%: shrinking)	100.00%	0.00%	Compare
IRLA Quince Therapeutics, Inc.	$33.8M	— (loss-making)	—	—	n/m	−63.65% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$35.5M	—	—	−28.98%	—	−15.07%	0.00%	0.00%

All 614 Biotechnology stocks →

Cassava Sciences, Inc. (FLNA) key facts

Cassava Sciences, Inc. (FLNA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, FLNA traded at $0.71, a market capitalization of $36.8 million.
Return on equity was −82.7% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.